Shen Fei, Huang Jihe, Yang Kejia, Sun Chunhua
Department of Orthopedics, Suzhou Wuzhong People's Hospital, Suzhou, People's Republic of China.
Onco Targets Ther. 2023 Jun 29;16:485-495. doi: 10.2147/OTT.S415399. eCollection 2023.
Bone metastasis is one of the most important factors associated with poor prognosis for patients with prostate, breast, thyroid, and lung cancer. In the past two decades, 651 clinical trials, including 554 interventional trials, were being registered in ClinicalTrials.gov and pharma.id.informa.com to combat bone metastases from different perspectives. In this review, we comprehensively analyzed, regrouped, and discussed all the interventional trials on bone metastases. Clinical trials were re-grouped into bone-targeting agents, radiotherapy, small molecule targeted therapy, combination therapy, and others, based on the different mechanisms of action including modifying the bone microenvironment and preventing the growth of cancer cells. We also discussed the potential strategies that might improve overall survival and progression-free survival of patients with bone metastases in the future.
骨转移是前列腺癌、乳腺癌、甲状腺癌和肺癌患者预后不良的最重要因素之一。在过去二十年中,ClinicalTrials.gov和pharma.id.informa.com网站上登记了651项临床试验,其中包括554项干预性试验,旨在从不同角度对抗骨转移。在本综述中,我们对所有关于骨转移的干预性试验进行了全面分析、重新分组并展开讨论。基于包括改变骨微环境和阻止癌细胞生长等不同作用机制,临床试验被重新分为骨靶向药物、放射治疗、小分子靶向治疗、联合治疗及其他类别。我们还讨论了未来可能改善骨转移患者总生存期和无进展生存期的潜在策略。